The challenges of delivering health care in the enlarged European Union were discussed last month in Sunny Beach, Bulgaria. The conference was financed by the European Commission and organized by the Bulgarian Faculty of Public Health of the Medical University, with the cooperation of the Ministry of Health and the National Health Insurance Fund. A number of significant topics for Bulgarian health care were discussed, according to the country's Association of Research-based Pharmaceutical Manufacturers (ARPharM).
A working panel on pharmaceutical policy and legislation was held, at which James Copping of the Commission, Svetlana Spasova, Director of National Health Policy at the Bulgarian MoH, and pharmaceutical industry representatives presented their view. They adopted the idea that constructive and good-will-based discussion with the participation of all the parties concerned, is needed to guarantee the building of common health and drugs policy, to find the crossing point between providing Bulgarian patients access to up-to-date and effective medicine treatment and the pharmaceutical industry with the opportunity to work in a predictable market environment and receive reward for innovation, so as to continue the research for new medicines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze